1878. Expanding Kentucky’s ‘One and Done’ Tradition: Lipoglycopeptide Administration in the Emergency Department at a Tertiary, Academic Medical Center
Session: Poster Abstract Session: Antimicrobial Stewardship: Potpourri
Saturday, October 6, 2018
Room: S Poster Hall
  • Dalbavancin Poster (ID Week).pdf (104.7 kB)
  • Background:

    Acute bacterial skin and skin structure infection (ABSSSI) incidence continues to rise, accounting for around 3.5 million emergency department (ED) visits per year in the US. Dalbavancin and oritavancin are lipoglycopeptides with long half-lives allowing for single dose treatment options for eligible patients presenting with ABSSSIs in the ED, avoiding an inpatient admission. The objective of this study was to investigate the financial outcomes of utilizing these agents in the ED.


    This was a single-center, retrospective study in adult patients with ABSSSIs that received a lipoglycopeptide in the ED at an academic medical center from April 2016 to February 2018. A multi-disciplinary institutional guideline was developed and implemented in April 2016. Data was documented in the electronic medical record and/or REDCapTM database. A comparator group was identified by utilizing similar ICD-10 codes for patients that were admitted for ABSSSI. Variable direct cost-avoidance was examined to explore the financial implication of lipoglycopeptide treatment in this population.


    The average length of stay in the comparator group who were admitted for ABSSSIs during the predefined time period was 4.3 days. Because patients receiving a lipoglycopeptide did not require admission for intravenous antibiotics, 94.6 patient days were avoided increasing the capacity by 14.1 patients. Overall, 22 patients received either dalbavancin (n=18) or oritavancin (n=4). The age was 40.8 +/- 13.2 years for the study group with 55% male. The age of the comparator group was 40.5 +/- 19.7 years. All patients were discharged home from the ED without being admitted. Two patients were readmitted for treatment failure requiring IV antibiotics. Despite 2 of 22 patients receiving a lipoglycopeptide without insurance, the variable direct cost-avoidance was $4,560 per case, or $1,060 per day.


    The use of lipoglycopeptides offers patient convenience and financial benefits, warranting its consideration for use in the ED at tertiary academic medical centers.

    Donna R. Burgess, RPh1,2, Garrett Hile, PharmD1, Jeffrey Reynolds, MBA1, Sarah Cotner, PharmD, BCPS2, Regan Baum, PharmD1,2, Abby M. Bailey, PharmD, BCPS1,2, Thein Myint, MBBS3 and Katie L. Wallace, PharmD, BCPS1,2, (1)University of Kentucky HealthCare, Lexington, KY, (2)University of Kentucky, College of Pharmacy, Lexington, KY, (3)Division of Infectious Diseases, University of Kentucky, Lexington, KY


    D. R. Burgess, None

    G. Hile, None

    J. Reynolds, None

    S. Cotner, None

    R. Baum, None

    A. M. Bailey, None

    T. Myint, None

    K. L. Wallace, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.